Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled,…

878 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers (2019, background): “daily allowance is not recommended because it does not alter glycemic measures, cardiovascular riskmeasures, or the rate at which glomerular filtration rate declines (116,117).”
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “Women Manage women with the same pharmacological therapy as that for men for acute care and secondary prevention, with attention to weight and/or renally calculated doses of antiplatelet and anticoagulant agents to reduce bleeding risk I B (311-315)”
Pathophysiology of human visceral obesity: an update. (2013, background): “The other drug approved is actually a combination of phentermine, a central norepinephrine-releasing agent, with topiramate which has been used for the treatment of epilepsy and migraine (172, 183).”
Pharmacological management of obesity: an endocrine Society clinical practice guideline. (2015, background): “The product label recommends a gradual reduction of dose over 3–5 days because of the observation of seizures occurring when topiramate was stopped abruptly in patients with epilepsy (41, 43, 61).”